Previous 10 | Next 10 |
The fund just received a huge distribution boost, making it more appealing to income-oriented investors. The latest declines in BMEZ also coincide with an attractive discount on the fund. BMEZ is an attractive long-term option in the healthcare space that focuses on new tech - tho...
The following slide deck was published by Kymera Therapeutics, Inc. in conjunction with this event. For further details see: Kymera Therapeutics (KYMR) Investor Presentation - Slideshow
WATERTOWN, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Elena Ridloff, CFA,...
Kymera Therapeutics (KYMR): Q4 GAAP EPS of -$0.29 misses by $0.12.Revenue of $12.8M (+599.5% Y/Y) misses by $8.8M.Press Release For further details see: Kymera Therapeutics EPS misses by $0.12, misses on revenue
Initiated Phase 1 first-in-human dosing of KT-474, a first-in-class oral IRAK4 degrader to treat immune-inflammatory diseases Declared KT-333 as STAT3 development candidate for liquid and solid tumor indications and commenced IND-enabling activities Strong financial posi...
Kymera Therapeutics is a next-generation targeted protein degradation company working to drug the undruggable genome. The company's platform has attracted three biopharma deals worth more than $3B. Kymera is filing three investigational drug applications in 2021 that might create ...
KT-474 is the first IRAK4 degrader, and first heterobifunctional small molecule protein degrader outside of oncology, to enter clinical development Phase 1 trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered KT-474 in healthy ...
WATERTOWN, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in upcoming investor...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead A four-day trading week will see investors tackle the question of how inflation and rising interest rates could come int...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
News, Short Squeeze, Breakout and More Instantly...
Kymera Therapeutics Inc. Company Name:
KYMR Stock Symbol:
NASDAQ Market:
Kymera Therapeutics Inc. Website:
2024-07-12 19:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 13:30:00 ET Shares of Kymera Therapeutics (NASDAQ: KYMR) were soaring 18.4% higher as of 11:28 a.m. ET on Tuesday. The big jump came after the clinical-stage biopharmaceutical company announced on Monday that its partner, Sanofi , plans to expand the ongoing phase 2 s...
WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside ...